Elanco Animal Health
↗Indianapolis, USA
Elanco Animal Health is a global leader in the animal health industry, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company provides a broad portfolio of parasiticides, vaccines, and therapeutic products, serving veterinarians, farmers, and pet owners worldwide.
Headquartered in Indianapolis, Indiana, Elanco operates as an independent, publicly traded company following its divestiture from Eli Lilly and Company in 2019. The company focuses on sustainable growth through a robust pipeline of innovation, including monoclonal antibodies and immunotherapy platforms, aiming to address significant challenges in animal, human, and environmental health.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$4B-$5B
Founded:1954
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:ELAN
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Immunotherapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pharmaceutical Supply Chain Initiative (PSCI) member
COMPETITION
Position:Leader
Competitors:Zoetis, Boehringer Ingelheim Animal Health, Merck Animal Health, IDEXX Laboratories
LEADERSHIP
Key Executives:
Jeff Simmons - CEO
LINKS
Website:elancoah.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Elanco Animal Health and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Elanco Animal Health. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.